Allied Market Research
Loading...
0

Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications), Pain Type (Chronic and Acute) : Global Opportunity Analysis and Industry Forecast, 2019–2027

A00309
Pages: 266
Sep 2020 | 22026 Views
   
Author(s) : Ravi Telugunta, Komal Urde , Onkar Sumant
Tables: 125
Charts: 55
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Pain Management Drugs Market

Request Now !

The global pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach $91,649.16 million by 2027, registering a CAGR of 3.8% from 2020 to 2027. 

Pain is a disturbing sensory and emotional sensation that results from tissue damage or disease. In addition, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer. The length of pain ranges from acute pain for short term to chronic pain for long term. Acute pain can be mild and lasts for only a moment or for weeks, or months. Chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. A variety of drugs are used to manage pain resulting from inflammation in response to tissue damage, chemical agents/pathogens (nociceptive pain) or nerve damage (neuropathic pain). Most drugs act by binding to protein targets on cell membranes and affecting biochemical processes of the body.

Pain-Management-Drugs-Market-2020-2027

Get more information on this report : Request Sample Pages

Rise in geriatric population is the major factor that drives growth of the global pain management drugs market as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the pain management drugs market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

COVID-19 pandemic, which started from Wuhan city of China, has widespread across the globe. This pandemic has disrupted growth in many economies across various domains. The COVID-19 outbreak is expected to impact the pain management drugs market in the initial phase of during the forecast period. The COVID-19 pandemic has stressed healthcare systems worldwide, so many clinics and pain services are no longer open for public services, owing to of safety measures imposed by governments. Subsequently, most chronic pain facilities were deemed non-urgent, both outpatient and elective interventional procedures were limited or stopped during the COVID-19 pandemic to minimize risk of the viral spread. Furthermore, during the latter half of the forecast period, demand for pain management drugs is expected to rise, owing to factors such as telemedicine, which has become an appropriate and effective way to offer necessary medical services to patients with chronic pain.

The global pain management drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, it is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia, bone fracture, muscle sprain, acute appendicitis and other indications.  On the basis of pain type, it is segmented into chronic pain and acute pain. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Pain Management Drugs Market
By Drug Class

Your browser does not support the canvas element.

Opiods is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Drug class segment review

By drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anesthetics segment is anticipated to possess highest growth rate during the forecast period.

Pain Management Drugs Market
By Indication

Your browser does not support the canvas element.

Cancer pain is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Segment review

By indication, the neuropathic pain segment accounted for a majority of the market share in 2019, and is expected to exhibit a prominent growth rate during the forecast period. In addition, increase in presence of large patient population is the major factor that increases demand for drugs for the segment. Cancer pain and chronic back pain segments are expected to grow at the highest rate throughout the forecast period, owing to increase in number of surgeries globally and rise in prevalence of chronic diseases that lead to back pain. 

On the basis of pain type, the chronic pain segment was the largest contributor to the market growth in 2019, and is expected to grow at a CAGR of 3.9% during the forecast period.

Pain Management Drugs Market
By Pain Type

Your browser does not support the canvas element.

Chronic Pain is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

North America accounted for majority of the pain management drugs market share in 2019, and is expected to remain dominant throughout the forecast period. This was attributed to large number of aging population and favorable regulatory conditions. Rise in number of drug abuse cases and addictive nature of opioids has decreased use of prescriptions for opioids in the region, leading to decline in opioid consumption for pain management. On the other hand, Asia-Pacific is expected to experience highest growth rate during the forecast period, mainly attributable to presence of larger patient pool and increase in healthcare expenditure in the region.

Some of the key players operating in the market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. The other prominent players in the value chain include Allergen Inc., Bayer AG, Bristol-Myers Squibb, Valeant Pharmaceuticals International Inc., Boehringer Ingelheim, Sorrento Therapeutics, WEX Pharmaceuticals, and Zynerba Pharmaceuticals.

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the pain management drugs market growth is provided in the report.
  • The pain management drugs market forecast is studied from 2020 to 2027
  • Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.
  • Key market players and their strategies have been analysed to understand the competitive outlook of the pain management drugs market.

Key Market Segments

By Drug Class

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Anti-migraine Agents
  • Antidepressants
  • Opioids 
  • Nonnarcotic Analgesics 

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Muscle sprain/strain
  • Bone fracture 
  • Acute appendicitis
  • Others

By Pain Type 

  • Chronic pain 
  • Acute pain 

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
1.4.4.Primary research

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top winning strategies

3.3.Top player positioning
3.4.Porter’s five force analysis for North America
3.5.Government regulations
3.6.Market dynamics

3.6.1.Drivers

3.6.1.1.Rise in incidences of chronic diseases
3.6.1.2.Favorable regulatory scenario
3.6.1.3.Increase in geriatric population

3.6.2.Restraints

3.6.2.1.Availability of alternative therapies
3.6.2.2.Drug exploitation
3.6.2.3.Patent expiration of prescription drugs

3.6.3.Opportunities

3.6.3.1.Advancements in drug development
3.6.3.2.Untapped markets in developing economies

3.7.North America pricing for pain management drugs
3.8.Standard of care for pain management in North America
3.9.Reimbursement scenario in North America
3.10.COVID-19 impact analysis for North America Pain Management Drugs

CHAPTER 4:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.NSAIDS

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.2.4.Market analysis, by country

4.3.Anesthetics

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Anticonvulsants

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Antimigraine drug

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.Antidepressant drugs

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

4.7.Opioids

4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country

4.8.Non-narcotic analgesics

4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country

CHAPTER 5:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Arthritic pain

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Neuropathic pain

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Cancer pain

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Chronic back pain

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Post-operative pain

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

5.7.Migraine

5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country

5.8.Fibromyalgia

5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country

5.9.Bone fracture

5.9.1.Market size and forecast, by region
5.9.2.Market analysis, by country

5.10.Muscle sprain/strain

5.10.1.Market size and forecast, by region
5.10.2.Market analysis, by country

5.11.Acute appendicitis

5.11.1.Market size and forecast, by region
5.11.2.Market analysis, by country

5.12.Others

5.12.1.Market size and forecast, by region
5.12.2.Market analysis, by country

CHAPTER 6:PAIN MANAGEMENT DRUGS, BY PAIN TYPE

6.1.Overview

6.1.1.Market size and forecast

6.2.Chronic pain

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Acute pain

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

CHAPTER 7:PAIN MANAGEMENT DRUGS MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America pain management drugs market, by country

7.2.2.1.U.S. Pain management drugs market, by drug class
7.2.2.2.U.S pain management drugs market, by indications
7.2.2.3.U.S pain management drugs market, by pain type
7.2.2.4.Canada pain management drugs market, by drug class
7.2.2.5.Canada pain management drugs market, by indication
7.2.2.6.Canada pain management drugs market, by pain type
7.2.2.7.Mexico pain management drugs market, by drug class
7.2.2.8.Mexico pain management drugs market, by indication
7.2.2.9.Mexico pain management drugs market, by pain type

7.2.3.North America pain management drugs market, by drug class
7.2.4.North America pain management drugs market, by indication
7.2.5.North America pain management drugs market, by pain type

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe pain management drugs market, by country

7.3.2.1.UK pain management drugs market, by drug class
7.3.2.2.UK pain management drugs market, by indication
7.3.2.3.UK pain management drugs market, by pain type
7.3.2.4.Germany pain management drugs market, by drug class
7.3.2.5.Germany pain management drugs market, by indication
7.3.2.6.Germany pain management drugs market, by pain type
7.3.2.7.France pain management drugs market, by drug class
7.3.2.8.France pain management drugs market, by indication
7.3.2.9.France pain management drugs market, by pain type
7.3.2.10.Italy pain management drugs market, by drug class
7.3.2.11.Italy pain management drugs market, by indication
7.3.2.12.Italy pain management drugs market, by pain type
7.3.2.13.Spain management drugs market, by drug class
7.3.2.14.Spain Management Drugs Market, by indication
7.3.2.15.Spain management drugs market, by pain type
7.3.2.16.Rest of Europe pain management drugs market, by drug class
7.3.2.17.Rest of Europe Pain Management Drugs Market, by indication
7.3.2.18.Rest of Europe pain management drugs market, by pain type

7.3.3.Europe pain management drugs market, by drug class
7.3.4.Europe pain management drugs market, by indication
7.3.5.Europe pain management drugs market, by pain type

7.4.Asia Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific pain management drugs market, by country

7.4.2.1.Japan pain management drugs market, by drug class
7.4.2.2.Japan pain management drugs market, by indications
7.4.2.3.Japan Pain Management Drugs Market, by pain type
7.4.2.4.China pain management drugs market, by drug class
7.4.2.5.China pain management drugs market, by indications
7.4.2.6.China pain management drugs market, by pain type
7.4.2.7.Australia pain management drugs market, by drug class
7.4.2.8.Australia pain management drugs market, by indications
7.4.2.9.Australia pain management drugs market, by pain type
7.4.2.10.India pain management drugs market, by drug class
7.4.2.11.India pain management drugs market, by indications
7.4.2.12.India pain management drugs market, by pain type
7.4.2.13.Rest of Asia-Pacific pain management drugs market, by drug class
7.4.2.14.Rest of Asia-Pacific pain management drugs market, by indications
7.4.2.15.Rest of Asia-Pacific pain management drugs market, by pain type

7.4.3.Asia-Pacific pain management drugs market, by drug Class1
7.4.4.Asia-Pacific pain management drugs market, by indication
7.4.5.Asia-Pacific pain management drugs market, by pain type

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA pain management drugs market, by country

7.5.2.1.Brazil pain management drugs market, by drug class
7.5.2.2.Brazil pain management drugs market, by indication
7.5.2.3.Brazil pain management drugs market, by pain type
7.5.2.4.Saudi Arabia pain management drugs market, by drug class
7.5.2.5.Saudi Arabia pain management drugs market, by indication
7.5.2.6.Saudi Arabia pain management drugs market, by pain type
7.5.2.7.South Africa pain management drugs Market, by drug class
7.5.2.8.South Africa Pain Management Drugs Market, by indication
7.5.2.9.South Africa pain management drugs market, by pain type
7.5.2.10.Rest of LAMEA pain management drugs market, by drug class
7.5.2.11.Rest of LAMEA pain management drugs market, by indication
7.5.2.12.Rest of LAMEA pain management drugs market, by pain type

7.5.3.LAMEA pain management drugs market, by drug Class
7.5.4.LAMEA pain management drugs market, by indication
7.5.5.LAMEA pain management drugs market, by drug Class

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance

8.2.ELI LILY AND COMPANY

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.ENDO HEALTH SOLUTIONS, INC. (ENDO INTERNATIONAL PLC.)

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance 

8.4.GLAXOSMITHKLINE PLC (GSK) 

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.JOHNSON & JOHNSON

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.MERCK & CO., INC. 

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.MYLAN N.V.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.NOVARTIS INTERNATIONAL AG

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.PFIZER INC. 

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.PURDUE PHARMA L.P. 

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Key strategic moves and developments

LIST OF TABLES

TABLE 01.PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 02.PAIN MANAGEMENT DRUGS MARKET, BY NSAIDS, BY REGION, 2019–2027 ($MILLION) 
TABLE 03.PAIN MANAGEMENT DRUGS MARKET, BY ANESTHETIC, BY REGION, 2019–2027 ($MILLION) 
TABLE 04.PAIN MANAGEMENT DRUGS MARKET, BY ANTICONVULSANT, BY REGION, 2019–2027 ($MILLION) 
TABLE 05.PAIN MANAGEMENT DRUGS MARKET, BY ANTIMIGRAINE DRUG, BY REGION, 2019–2027 ($MILLION) 
TABLE 06.PAIN MANAGEMENT DRUGS MARKET, BY ANTIDEPRESSANT DRUGS, BY REGION, 2019–2027 ($MILLION) 
TABLE 07.PAIN MANAGEMENT DRUGS MARKET, BY OPIOIDS, BY REGION, 2019–2027 ($MILLION) 
TABLE 08.PAIN MANAGEMENT DRUGS MARKET, BY NON-NARCOTIC ANALGESICS, BY REGION, 2019–2027 ($MILLION) 
TABLE 09.PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 10.PAIN MANAGEMENT DRUGS MARKET, BY ARTHMITIC PAIN, BY REGION, 2019–2027 ($MILLION) 
TABLE 11.PAIN MANAGEMENT DRUGS MARKET, BY NEUROPATHIC PAIN, BY REGION, 2019–2027 ($MILLION) 
TABLE 12.PAIN MANAGEMENT DRUGS MARKET, BY CANCER PAIN, BY REGION, 2019–2027 ($MILLION) 
TABLE 13.PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC BACK PAIN, BY REGION, 2019–2027 ($MILLION) 
TABLE 14.PAIN MANAGEMENT DRUGS MARKET, BY POST-OPERATIVE PAIN, BY REGION, 2019–2027 ($MILLION) 
TABLE 15.PAIN MANAGEMENT DRUGS MARKET, BY MIGRAINE, BY REGION, 2019–2027 ($MILLION) 
TABLE 16.PAIN MANAGEMENT DRUGS MARKET, BY FIBROMYALGIA, BY REGION, 2019–2027 ($MILLION) 
TABLE 17.PAIN MANAGEMENT DRUGS MARKET, BY BONE FRACTURE, BY REGION, 2019–2027 ($MILLION) 
TABLE 18.PAIN MANAGEMENT DRUGS MARKET, BY MUSCLE SPRAIN, BY REGION, 2019–2027 ($MILLION) 
TABLE 19.PAIN MANAGEMENT DRUGS MARKET, BY ACUTE APPENDICITIS, BY REGION, 2019–2027 ($MILLION) 
TABLE 20.PAIN MANAGEMENT DRUGS MARKET, BY OTHERS, BY REGION, 2019–2027 ($MILLION) 
TABLE 21.PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 22.PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC PAIN, BY REGION, 2019–2027 ($MILLION) 
TABLE 23.PAIN MANAGEMENT DRUGS MARKET, BY ACUTE PAIN, BY REGION, 2019–2027 ($MILLION) 
TABLE 24.GLOBAL PAIN MANAGEMENT DRUGS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION) 
TABLE 25.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION) 
TABLE 26.U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 27.U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION) 
TABLE 28.U.S. PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 29.CANADA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 30.CANADA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 31.CANADA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 32.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 33.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 34.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 35.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 36.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 37.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 38.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION) 
TABLE 39.UK PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 40.UK PAIN MANAGEMENT DRUGS MARKET , BY INDICATION, 2019–2027 ($MILLION) 
TABLE 41.UK PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 42.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 43.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 44.GERMNAY PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 45.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 46.FRNACE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 47.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 48.ITALY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 49.ITALY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 50.ITALY PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 51.SPAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 52.SPAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 53.SPAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 54.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 55.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 56.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 57.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 58.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 59.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 60.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION) 
TABLE 61.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 62.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION) 
TABLE 63.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 64.CHINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 65.CHINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION) 
TABLE 66.CHINA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 67.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 68.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION) 
TABLE 69.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 70.INDIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 71.INDIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION) 
TABLE 72.INDIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 73.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 74.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION) 
TABLE 75.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 76.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 77.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 78.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 79.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION) 
TABLE 80.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 81.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 82.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 83.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 84.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 85.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 86.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 87.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 88.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 89.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 90.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 91.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION) 
TABLE 92.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 93.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION) 
TABLE 94.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION) 
TABLE 95.ABBOTT: COMPANY SNAPSHOT
TABLE 96.ABBOTT: OERATING SEGMENT
TABLE 97.ABBOTT: PRODUCT PORTFOLIO
TABLE 98.ELI LILLY: COMPANY SNAPSHOT
TABLE 99.LILLY: OPERATING SEGMENTS
TABLE 100.ELI LILLY: PRODUCT PORTFOLIO
TABLE 101.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102.ENDO: COMPANY SNAPSHOT
TABLE 103.ENDO: OPERATING BUSINESS SEGMENTS
TABLE 104.ENDO: PRODUCT PORTFOLIO
TABLE 105.GSK: COMPANY SNAPSHOT
TABLE 106.GSK: OPERATING SEGMENTS
TABLE 107.GSK: PRODUCT PORTFOLIO
TABLE 108.J&J: COMPANY SNAPSHOT
TABLE 109.J&J: OPERATING BUSINESS SEGMENTS
TABLE 110.J&J: PRODUCT PORTFOLIO
TABLE 111.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 112.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 113.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 114.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115.MYLAN: COMPANY SNAPSHOT
TABLE 116.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 117.MYLAN: PRODUCT PORTFOLIO
TABLE 118.NOVARTIS: COMPANY SNAPSHOT
TABLE 119.NOVARTIS: OPERATING SEGMENTS
TABLE 120.NOVARTIS: PRODUCT PORTFOLIO
TABLE 121.PFIZER: COMPANY SNAPSHOT
TABLE 122.PFIZER: OERATING SEGMENT
TABLE 123.PFIZER: PRODUCT PORTFOLIO
TABLE 124.PURDUE: COMPANY SNAPSHOT
TABLE 125.PURDUE: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES, 2017–2020
FIGURE 03.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 05.TOP PLAYER POSTIONING, 2019
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODEARTE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE OF RIVALRY
FIGURE 11.DRIVER, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS BY COUNTRY,  2019 & 2027 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANESTHETIC BY COUNTRY, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANT BY COUNTRY, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIMIGRAINE BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANT DRUGS BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS BY COUNTRY,  2019 & 2027 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC ANALGESICS BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ARTHMITIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CANCER PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC BACK PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINE, BY COUNTRY,  2019 & 2027 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA BY COUNTRY, 2019 & 2027 (%)
FIGURE 26.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR BONE FRACTURE BY COUNTRY, 2019 & 2027 (%)
FIGURE 27.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR MUSCLE SPRAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 28.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE APPENDICITIS BY COUNTRY, 2019 & 2027 (%)
FIGURE 29.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR OTHERS BY COUNTRY,  2019 & 2027 (%)
FIGURE 30.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 31.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 32.ABBOTT: NET SALES, 2017–2019 ($MILLION) 
FIGURE 33.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 34.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 35.ELI LILLY: NET SALES, 2017–2019 ($MILLION) 
FIGURE 36.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 37.ENDO: NET SALES, 2017–2019 ($MILLION) 
FIGURE 38.ENDO: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 39.GSK: NET SALES, 2017–2019 ($MILLION) 
FIGURE 40.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 41.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 42.J&J: NET SALES, 2017–2019 ($MILLION) 
FIGURE 43.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 44.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 45.MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION) 
FIGURE 46.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 47.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 48.MYLAN: NET SALES, 2017–2019 ($MILLION) 
FIGURE 49.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 50.NOVARTIS: NET SALES, 2017–2019 ($MILLION) 
FIGURE 51.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 52.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 53.PFIZER: NET SALES, 2017–2019 ($MILLION) 
FIGURE 54.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 55.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)

 
 

The demand for pain management drugs has increased rapidly over recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors to the market growth. Presence of large geriatric population base, rise in global prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases contribute to growth of the market. 

However, patent expiration of major best-seller drugs such as pregabalin and duloxetine by Pfizer and Eli Lilly & Co., respectively, and availability of alternative therapies such as acupuncture, massage, and medical devices hamper the market growth.

Employment of pain management drugs is the highest in North America, owing to increase in adoption of these drugs, high prevalence of chronic diseases, and increase in disposable income of customers. In addition, presence of a large geriatric population and favorable regulatory & healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010 supplement the market growth. 

Although the use of pain management drugs in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase, owing to rise in disposable income and surge in incidences of chronic diseases. China and India are potential markets in Asia-Pacific. Moreover, increase in R&D investments, upsurge in healthcare expenditure, and rise in government funding & initiatives propel the market growth in Asia-Pacific.
 

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total value of Pain Management Drugs market was $71,431.85 million in 2019.

A. The forecast period in the report is from 2020-2027.

A. The market value of Pain Management Drugs market in 2020 was $70,742.38 million.

A. The base year calculated is 2019 in the report.

A. The demand for pain management drugs has increased rapidly over recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors to the market growth. Presence of large geriatric population base, rise in global prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases contribute to growth of the market.

A. Rise in geriatric population is the major factor that drives growth of the global pain management market as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

A. The growth % of the Pain Management Drugs market is 3.8%.

A. Opioids segment holds the maximum market share.

Allied Market Research Allied Market Research Allied Market Research

RELATED TAGS

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Pain Management Drugs Market

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers